Transaction

Transaction Details

Closed
February 25, 2021

Sector

Industrials and Industrial Technology

Deal Type

Mergers and Acquisitions

Previous Next

GCA advises Arcline on its acquisition of ChargePoint

GCA has advised Arcline Investment Management, a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, on its acquisition of ChargePoint Technology Holdings Limited, a leading manufacturer of containment and aseptic powder transfer technologies.

ChargePoint is headquartered in Liverpool, UK. Its products are used primarily in pharmaceutical manufacturing and bioprocessing applications and include multi-use and single-use split butterfly valves, charge bottles and bags, process solution accessories, and spare parts. These mission-critical technologies enable ChargePoint’s customers, including all the top 20 global pharmaceutical companies, to establish safe and reliable manufacturing process environments.

The transaction is the inaugural investment of Arcline’s second fund and marks an exit for LDC following a four-year partnership with ChargePoint. ChargePoint is anticipated to be the first of several acquisitions as Arcline builds a specialty process technologies platform focused on pharmaceutical and biopharmaceutical end markets.

Arcline commented, "ChargePoint supports the production of life-saving therapies by providing best-in-class containment and aseptic transfer technologies to pharmaceutical and biopharmaceutical companies. Specifically, the Company’s products provide industry-leading solutions for handling highly potent active pharmaceutical ingredients (HPAPIs) and sterile drug products across the most demanding drug manufacturing applications in the areas of oncology, diabetes, and other highly toxic therapies. We are committed to supporting ChargePoint in its next phase of growth through investments in product development, go-to-market capabilities, and add-on acquisitions.”

Chris Eccles, CEO of ChargePoint, said: “We are excited to partner with Arcline, a firm that shares our passion for providing our customers with safer containment and sterile transfer technologies, which are critical to the future of medicine. We look forward to expanding our critical role in pharmaceutical manufacturing and bioprocessing as we invest in our next phase of growth.”

Previous Next
All Transactions